NovaBay Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
SDEV$0.89-9.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. FINANCIAL STATEMENTS
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par value amounts)
| June 30, 2024 | December 31, 2023 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $751 | $2,924 |
| Accounts receivable, net of allowance for credit losses ($3 at June 30, 2024 and December 31, 2023) | 547 | 680 |
| Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($204 and $264 at June 30, 2024 and December 31, 2023, respectively) | 700 | 564 |
| Prepaid expenses and other current assets | 255 | 256 |
| Current assets, discontinued operations | — | 2,730 |
| Total current assets | 2,253 | 7,154 |
| Operating lease right-of-use assets | 1,128 | 1,296 |
| Property and equipment, net | 68 | 87 |
| Other assets | 476 | 478 |
| Other assets, discontinued operations | — | 19 |
| TOTAL ASSETS | $3,925 | $9,034 |
| LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||
| Liabilities: | ||
| Current liabilities: | ||
| Accounts payable | $1,235 | $906 |
| Accrued liabilities | 1,297 | 1,169 |
| Secured Convertible Notes, net of discounts | 655 | 1,137 |
| Unsecured Convertible Notes, net of discounts | 41 | — |
| Operating lease liabilities | 382 | 368 |
| Current liabilities, discontinued operations | — | 698 |
| Total current liabilities | 3,610 | 4,278 |
| Warrant liabilities | — | 334 |
| Operating lease liabilities-non-current | 932 | 1,108 |
| Total liabilities | 4,542 | 5,720 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ (deficit) equity: | ||
| Preferred stock, $0.01 par value; 5,000 shares authorized; | ||
| Series B Preferred Stock; 1 and 6 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively | 6 | 275 |
| Series C Preferred Stock; 0 and 1 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively | — | 1,675 |
| Common stock, $0.01 par value; 150,000 shares authorized, 1,348 and 321 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively* | 13 | 3 |
| Additional paid-in capital* | 179,392 | 176,210 |
| Accumulated deficit | (180,028) | (174,849) |
| Total stockholders’ (deficit) equity | (617) | 3,314 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | $3,925 | $9,034 |
| * | After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. |
|---|
-3-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.